# Expeditors International of Washington Inc: financial statements, quarterly

EXPD · NYSE · CIK 746515 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/expd.md) · [Financials](/companies/expd/financials.md) · [Filings](/companies/expd/filings.md) · [Insiders](/companies/expd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/expd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,190](/filings/0000950170-24-121496.md) | [2,278 d](/filings/0001193125-26-071569.md) | [2,207](/filings/0000950170-25-066562.md) | [2,439](/filings/0000746515-25-000007.md) | [3,000](/filings/0001193125-25-268710.md) | [2,955 d](/filings/0001193125-26-071569.md) | [2,666](/filings/0001193125-26-208834.md) | [2,652](/filings/0001193125-26-334457.md) | [2,895](/filings/0001193125-25-268710.md) | [2,856 d](/filings/0001193125-26-071569.md) | [2,783](/filings/0001193125-26-208834.md) | [3,502](/filings/0001193125-26-334457.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [216](/filings/0000950170-24-121496.md) | [199 d](/filings/0001193125-26-071569.md) | [215](/filings/0000950170-25-066562.md) | [224](/filings/0000746515-25-000007.md) | [302](/filings/0001193125-25-268710.md) | [301 d](/filings/0001193125-26-071569.md) | [266](/filings/0001193125-26-208834.md) | [248](/filings/0001193125-26-334457.md) | [288](/filings/0001193125-25-268710.md) | [251 d](/filings/0001193125-26-071569.md) | [295](/filings/0001193125-26-208834.md) | [350](/filings/0001193125-26-334457.md) |
| Interest expense | $m | [1.6](/filings/0000950170-23-061159.md) | [0.2 d](/filings/0000950170-24-019394.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [61.0](/filings/0000950170-24-121496.md) | [57.2 d](/filings/0001193125-26-071569.md) | [62.8](/filings/0000950170-25-066562.md) | [60.8](/filings/0000746515-25-000007.md) | [82.5](/filings/0001193125-25-268710.md) | [77.1 d](/filings/0001193125-26-071569.md) | [71.8](/filings/0001193125-26-208834.md) | [74.1](/filings/0001193125-26-334457.md) | [75.1](/filings/0001193125-25-268710.md) | [61.1 d](/filings/0001193125-26-071569.md) | [76.4](/filings/0001193125-26-208834.md) | [91.2](/filings/0001193125-26-334457.md) |
| Net income | $m | [171](/filings/0000950170-24-121496.md) | [159 d](/filings/0001193125-26-071569.md) | [169](/filings/0000950170-25-066562.md) | [175](/filings/0000746515-25-000007.md) | [230](/filings/0001193125-25-268710.md) | [236 d](/filings/0001193125-26-071569.md) | [204](/filings/0001193125-26-208834.md) | [184](/filings/0001193125-26-334457.md) | [222](/filings/0001193125-25-268710.md) | [201 d](/filings/0001193125-26-071569.md) | [230](/filings/0001193125-26-208834.md) | [266](/filings/0001193125-26-334457.md) |
| Diluted EPS | $ per share | [1.16](/filings/0000950170-24-121496.md) | not reported | [1.17](/filings/0000950170-25-066562.md) | [1.24](/filings/0000746515-25-000007.md) | [1.63](/filings/0001193125-25-268710.md) | not reported | [1.47](/filings/0001193125-26-208834.md) | [1.34](/filings/0001193125-26-334457.md) | [1.64](/filings/0001193125-25-268710.md) | not reported | [1.71](/filings/0001193125-26-208834.md) | [2.03](/filings/0001193125-26-334457.md) |
| Basic EPS | $ per share | [1.16](/filings/0000950170-24-121496.md) | not reported | [1.18](/filings/0000950170-25-066562.md) | [1.24](/filings/0000746515-25-000007.md) | [1.63](/filings/0001193125-25-268710.md) | not reported | [1.48](/filings/0001193125-26-208834.md) | [1.35](/filings/0001193125-26-334457.md) | [1.65](/filings/0001193125-25-268710.md) | not reported | [1.72](/filings/0001193125-26-208834.md) | [2.03](/filings/0001193125-26-334457.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,639](/filings/0000950170-23-061159.md) | [1,513](/filings/0000950170-25-024750.md) | [1,370](/filings/0000950170-24-056466.md) | [1,272](/filings/0000950170-24-093558.md) | [1,293](/filings/0000950170-24-121496.md) | [1,148](/filings/0001193125-26-071569.md) | [1,319](/filings/0000950170-25-066562.md) | [1,156](/filings/0000746515-25-000007.md) | [1,190](/filings/0001193125-25-268710.md) | [1,314](/filings/0001193125-26-334457.md) | [1,316](/filings/0001193125-26-208834.md) | [1,031](/filings/0001193125-26-334457.md) |
| Current assets | $m | [3,512](/filings/0000950170-23-061159.md) | [3,435](/filings/0000950170-25-024750.md) | [3,374](/filings/0000950170-24-056466.md) | [3,697](/filings/0000950170-24-093558.md) | [4,083](/filings/0000950170-24-121496.md) | [3,660](/filings/0001193125-26-071569.md) | [3,641](/filings/0000950170-25-066562.md) | [3,652](/filings/0000746515-25-000007.md) | [3,675](/filings/0001193125-25-268710.md) | [3,756](/filings/0001193125-26-334457.md) | [3,652](/filings/0001193125-26-208834.md) | [4,007](/filings/0001193125-26-334457.md) |
| Total assets | $m | [4,578](/filings/0000950170-24-121496.md) | [4,524](/filings/0001193125-26-071569.md) | [4,488](/filings/0000950170-25-066562.md) | [4,788](/filings/0000746515-25-000007.md) | [5,171](/filings/0001193125-25-268710.md) | [4,754](/filings/0001193125-26-071569.md) | [4,757](/filings/0001193125-26-208834.md) | [4,786](/filings/0001193125-26-334457.md) | [4,780](/filings/0001193125-25-268710.md) | [4,894](/filings/0001193125-26-334457.md) | [4,782](/filings/0001193125-26-208834.md) | [5,135](/filings/0001193125-26-334457.md) |
| Current liabilities | $m | [1,667](/filings/0000950170-23-061159.md) | [1,704](/filings/0000950170-25-024750.md) | [1,826](/filings/0000950170-24-056466.md) | [2,161](/filings/0000950170-24-093558.md) | [2,376](/filings/0000950170-24-121496.md) | [2,066](/filings/0001193125-26-071569.md) | [1,990](/filings/0000950170-25-066562.md) | [2,116](/filings/0000746515-25-000007.md) | [2,048](/filings/0001193125-25-268710.md) | [2,073](/filings/0001193125-26-334457.md) | [2,041](/filings/0001193125-26-208834.md) | [2,559](/filings/0001193125-26-334457.md) |
| Shareholders' equity | $m | [2,490](/filings/0000950170-23-061159.md) | [2,390](/filings/0000950170-25-024750.md) | [2,195](/filings/0000950170-24-056466.md) | [2,176](/filings/0000950170-24-093558.md) | [2,357](/filings/0000950170-24-121496.md) | [2,223](/filings/0001193125-26-071569.md) | [2,286](/filings/0000950170-25-066562.md) | [2,195](/filings/0000746515-25-000007.md) | [2,280](/filings/0001193125-25-268710.md) | [2,356](/filings/0001193125-26-334457.md) | [2,284](/filings/0001193125-26-208834.md) | [2,119](/filings/0001193125-26-334457.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [190](/filings/0000950170-24-121496.md) | [158 d](/filings/0001193125-26-071569.md) | [257](/filings/0000950170-25-066562.md) | [127](/filings/0000746515-25-000007.md) | [90.0](/filings/0001193125-25-268710.md) | [250 d](/filings/0001193125-26-071569.md) | [343](/filings/0001193125-26-208834.md) | [179](/filings/0001193125-26-334457.md) | [201](/filings/0001193125-25-268710.md) | [283 d](/filings/0001193125-26-071569.md) | [309](/filings/0001193125-26-208834.md) | [179](/filings/0001193125-26-334457.md) |
| Capital expenditure | $m | [8.0](/filings/0000950170-24-121496.md) | [10.7 d](/filings/0001193125-26-071569.md) | [10.2](/filings/0000950170-25-066562.md) | [7.9](/filings/0000746515-25-000007.md) | [12.3](/filings/0001193125-25-268710.md) | [10.1 d](/filings/0001193125-26-071569.md) | [13.2](/filings/0001193125-26-208834.md) | [15.9](/filings/0001193125-26-334457.md) | [11.1](/filings/0001193125-25-268710.md) | [13.0 d](/filings/0001193125-26-071569.md) | [12.6](/filings/0001193125-26-208834.md) | [12.0](/filings/0001193125-26-334457.md) |
| Dividends paid | $m | [0.0](/filings/0000950170-24-121496.md) | [99.8 d](/filings/0001193125-26-071569.md) | not reported | [103](/filings/0000746515-25-000007.md) | [0.0](/filings/0001193125-25-268710.md) | [101 d](/filings/0001193125-26-071569.md) | not reported | [104](/filings/0001193125-26-334457.md) | [0.0](/filings/0001193125-25-268710.md) | [103 d](/filings/0001193125-26-071569.md) | not reported | [106](/filings/0001193125-26-334457.md) |
| Share repurchases | $m | [298](/filings/0000950170-24-121496.md) | [194 d](/filings/0001193125-26-071569.md) | [361](/filings/0000950170-25-066562.md) | [102](/filings/0000746515-25-000007.md) | [140](/filings/0001193125-25-268710.md) | [252 d](/filings/0001193125-26-071569.md) | [177](/filings/0001193125-26-208834.md) | [231](/filings/0001193125-26-334457.md) | [212](/filings/0001193125-25-268710.md) | [46.5 d](/filings/0001193125-26-071569.md) | [288](/filings/0001193125-26-208834.md) | [355](/filings/0001193125-26-334457.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [163](/filings/0000950170-23-061159.md) | [155](/filings/0000950170-24-056466.md) | [152](/filings/0000950170-24-093558.md) | [148](/filings/0000950170-24-121496.md) | [144](/filings/0000950170-25-066562.md) | [142](/filings/0000746515-25-000007.md) | [141](/filings/0001193125-25-268710.md) | [138](/filings/0001193125-26-208834.md) | [137](/filings/0001193125-26-334457.md) | [135](/filings/0001193125-25-268710.md) | [134](/filings/0001193125-26-208834.md) | [131](/filings/0001193125-26-334457.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 129,990,622 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-334457.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.